Axios is reporting that it has found a way to detect the presence of testosterone in a man’s semen using a chemical test.
According to Axios, the test, which is made by a company called BioXinetics, can detect testosterone in semen even when the man is not taking the pill.
“When a man has the test and the sperm test, the testosterone level in the semen is at its lowest,” says Dr. J.P. Dabney, chief medical officer at BioX.
“And that means when the test detects the presence or absence of testosterone, the sperm is free of testosterone.”
The test is currently in clinical trials, but Dabneys team is looking to expand to larger groups of men in order to get it approved.
The test has already been used in Europe to detect testosterone levels in men who are taking testosterone replacement therapy, and the results can be reported to the government in a form that is acceptable to the public.
The FDA has not approved the test for use in the U.S. because of its potential to interfere with medical treatment.
But the FDA recently approved the first study that found that it could detect testosterone when used to test a man for prostate cancer.
The new test is not the first to use a testosterone-based test to test for testosterone levels.
The company BioX is currently working on a test that detects testosterone levels when a man is taking testosterone.
The drug is known as the testosterone-releasing hormone (TRH), and its use in testosterone replacement is a relatively new and emerging medical treatment that involves taking testosterone shots.
But it is also a controversial drug, with several studies finding that it may increase the risk of prostate cancer by increasing levels of the prostate-specific antigen, or PSA.
So far, the FDA has approved the testosterone treatment for the treatment of men with metastatic prostate cancer, but not for prostate cancers that are relatively benign, such as prostate cancer in men with benign prostate hyperplasia, or BPH.
In addition, the drug is not approved for use for prostate surgery or to treat men who have had multiple prostate surgeries or for patients with cancer of the ovaries, since these patients tend to have higher testosterone levels than those in the general population.
BioX in June announced that it had filed a patent for a new test that can detect the level of testosterone that is released from the prostate when a testosterone shot is administered.
In August, the company filed a provisional patent for the test.
The final approval process for the new test has yet to be finalized, but the company expects to submit the final patent application in early 2018.
“We have been working on this for many years,” says Dabrows team leader Dr. David Loeber.
“Our current work is focused on testosterone-sensitive test kits.
And we think the test we are working on could be very useful to test men for high testosterone levels, as it is known to be detectable in semen.”
The team is working with the American Society for Reproductive Medicine to develop the test in order that it can be approved in the United States.
In Europe, BioX has been testing the new testosterone-detecting test in patients taking testosterone-lowering medications.
The testosterone-reducing drug Truvada is the most commonly prescribed testosterone-free treatment in Europe, according to the European Union, and is a common method of treating men with prostate cancer for men who also have BPH and prostate cancer of their ovaries.
The use of testosterone-replacement drugs is also common in the European countries that have legalized the drug, including the United Kingdom, Ireland, Portugal, France, Italy, and Spain.
A new testosterone test has been approved for patients taking the testosterone replacement medication.
In November, a British court ruled that the drug should be given to patients to treat BPH, because it was found to have an effect on the testicles.